Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 5/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Stryker Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$86.57 |
52 Week High | US$89.96 |
52 Week Low | US$64.71 |
Beta | 0.91 |
1 Month Change | -3.77% |
3 Month Change | 3.06% |
1 Year Change | 13.27% |
3 Year Change | 18.98% |
5 Year Change | n/a |
Change since IPO | 91.10% |
Recent News & Updates
Recent updates
Shareholder Returns
S1YK34 | BR Medical Equipment | BR Market | |
---|---|---|---|
7D | 1.3% | -0.5% | 0.5% |
1Y | 13.3% | -2.6% | 16.7% |
Return vs Industry: S1YK34 exceeded the BR Medical Equipment industry which returned -2.2% over the past year.
Return vs Market: S1YK34 underperformed the BR Market which returned 16.7% over the past year.
Price Volatility
S1YK34 volatility | |
---|---|
S1YK34 Average Weekly Movement | 3.0% |
Medical Equipment Industry Average Movement | 6.6% |
Market Average Movement | 4.7% |
10% most volatile stocks in BR Market | 8.6% |
10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: S1YK34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine S1YK34's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1941 | 52,000 | Kevin Lobo | www.stryker.com |
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Stryker Corporation Fundamentals Summary
S1YK34 fundamental statistics | |
---|---|
Market cap | R$664.09b |
Earnings (TTM) | R$17.44b |
Revenue (TTM) | R$108.80b |
37.1x
P/E Ratio6.0x
P/S RatioIs S1YK34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
S1YK34 income statement (TTM) | |
---|---|
Revenue | US$20.96b |
Cost of Revenue | US$7.55b |
Gross Profit | US$13.41b |
Other Expenses | US$10.05b |
Earnings | US$3.36b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 8.84 |
Gross Margin | 63.99% |
Net Profit Margin | 16.03% |
Debt/Equity Ratio | 56.4% |
How did S1YK34 perform over the long term?
See historical performance and comparison